These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31707859)

  • 1. Superiority Versus Noninferiority.
    Pfeffer G; Pinzur MS; Adams W
    Foot Ankle Int; 2020 May; 41(5):624-625. PubMed ID: 31707859
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals.
    Angeli F; Verdecchia P; Reboldi G
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):229-238. PubMed ID: 31650521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol adherence rates in superiority and noninferiority randomized clinical trials published in high impact medical journals.
    Bamat NA; Ekhaguere OA; Zhang L; Flannery DD; Handley SC; Herrick HM; Ellenberg SS
    Clin Trials; 2020 Oct; 17(5):552-559. PubMed ID: 32666826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninferiority Trials in Interventional Cardiology.
    Kolte D; Aronow HD; Abbott JD
    Circ Cardiovasc Interv; 2017 Aug; 10(8):. PubMed ID: 28790166
    [No Abstract]   [Full Text] [Related]  

  • 5. US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology: A Dangerous Precedent?
    Gyawali B; Kesselheim AS
    JAMA Oncol; 2019 May; 5(5):607-608. PubMed ID: 30920591
    [No Abstract]   [Full Text] [Related]  

  • 6. Pros and Cons of Noninferiority Trials.
    Ofori S; Tornberg SV; Kilpeläinen TP; Tikkinen KAO; Guyatt GH; Witte LPW
    Eur Urol Focus; 2023 Sep; 9(5):711-714. PubMed ID: 37880063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone: Cohort Study of FDA and Sponsor Communication, 2011-2017.
    Doshi P; Spence O; Kuzucan A; Powers JH
    JAMA Intern Med; 2019 May; 179(5):719-721. PubMed ID: 30830158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninferiority Clinical Trials: The Good, the Bad, and the Ugly.
    Lesaffre E
    Semin Liver Dis; 2018 May; 38(2):97-102. PubMed ID: 29871016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pivotal trials of orthopedic surgical devices in the United States: predominance of two-arm non-inferiority designs.
    Golish SR
    Trials; 2017 Jul; 18(1):348. PubMed ID: 28738891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninferiority trials in oral medicine.
    Antunes JLF; Domaneschi C; Lemos CA
    Oral Dis; 2019 Mar; 25(2):357-362. PubMed ID: 29766614
    [No Abstract]   [Full Text] [Related]  

  • 11. Noninferiority drug trials fail to report adequate methodological detail: an assessment of noninferiority trials from 2010 to 2015.
    Hong J; Tung A; Kinkade A; Tejani AM
    J Clin Epidemiol; 2019 Apr; 108():144-146. PubMed ID: 30529004
    [No Abstract]   [Full Text] [Related]  

  • 12. Applications of Noninferiority Trials in Interventional Pulmonology.
    Mahajan AK; Ost DE; Cole BF; Kinsey CM
    J Bronchology Interv Pulmonol; 2019 Jan; 26(1):6-9. PubMed ID: 30562280
    [No Abstract]   [Full Text] [Related]  

  • 13. Considerations for design and data analysis of noninferiority/superiority cardiovascular trials.
    Quan H; Li M; Zhao PL; Cho M; Zhang J; Wu Y
    J Biopharm Stat; 2013; 23(1):239-60. PubMed ID: 23331234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninferiority studies: Not inherently unethical.
    McCarren M; Semla TP
    Am J Health Syst Pharm; 2018 Jun; 75(12):915-918. PubMed ID: 29880527
    [No Abstract]   [Full Text] [Related]  

  • 15. Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials.
    Aberegg SK; Hersh AM; Samore MH
    J Gen Intern Med; 2018 Jan; 33(1):88-96. PubMed ID: 28875400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodological quality of oncology noninferiority clinical trials.
    Wayant C; Ross A; Vassar M
    Crit Rev Oncol Hematol; 2020 May; 149():102938. PubMed ID: 32172223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample Size for Biosimilar Trials: In Defense of Synthesis.
    Clark T; Jo SJ; Phillips A
    Ther Innov Regul Sci; 2018 May; 52(3):300-305. PubMed ID: 29714537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological aspects of superiority, equivalence, and non-inferiority trials.
    Stefanos R; Graziella D'; Giovanni T
    Intern Emerg Med; 2020 Sep; 15(6):1085-1091. PubMed ID: 32705494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of noninferiority and equivalence trials: ignoring trial design leads to differing and possibly misleading conclusions.
    Acuna SA; Dossa F; Baxter N
    J Clin Epidemiol; 2020 Nov; 127():134-141. PubMed ID: 32540386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inferiority of noninferiority trials.
    Udayasiri DK; Skandarajah A; Hayes IP
    ANZ J Surg; 2020 Mar; 90(3):203-205. PubMed ID: 32147920
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.